Back to Trial

Oracle Runs

Oracle findings and outcome history for A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome (NCT06312020).

Runs
4
Findings
4
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

No public readout found for NCT06312020 Phase 2 trial as of April 2026. Trial active not recruiting, recruitment complete per sponsor site, estimated primary completion March 2026. No press releases, topline results, or efficacy interpretations from sponsor or news. Evidence limited to trial listings without outcome framing.

Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM
Sponsoramgentrials.com
Clinical Trial Summary: HZNP-HZN-1116-201
Trial Status: Recruitment Complete. A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants with Sjogren's Syndrome.
ClinicalTrialsclinicaltrials.gov
NCT06312020: A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116
Status: Active, not recruiting. Estimated Primary Completion Date: March 2026. No results posted.
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

No public results or readout available. Trial is active/not recruiting with primary completion in Mar 2026. All sources are pre-results (protocol, status, Phase 1 safety, or promotional). No source reports efficacy data, met goals, or frames outcome as positive/negative for this exact trial.

Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:25 PM
Web Searchclinicaltrials.gov
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
Current status: Active, not recruiting. Estimated primary completion date: 2026-03-19. No results posted.
Web Searchpharmaceutical-technology.comJan 22, 2025, 12:00 AM
AMG-329 by Amgen for Sicca Syndrome (Sjogren): Likelihood of Approval
Currently in Phase II for Sjogren's. No historical data available to benchmark likelihood of approval. No efficacy results reported.
Web Searchtheglobeandmail.comAug 23, 2025, 12:00 AM
Amgen’s Phase 2 Study on HZN-1116: A Potential Breakthrough for Sjögren’s Syndrome
Promotional; describes ongoing trial (primary completion mid-2025 per older update) with no actual results, data, or efficacy outcomes reported.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM
ClinicalTrialsclinicaltrials.govOct 24, 2025, 12:00 AM
Study Details | NCT06312020 | ClinicalTrials.gov
ClinicalTrials.gov lists active not recruiting; primary completion 2026-03-19; hasResults=false on the latest posted update.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found. Amgen said in February 2026 that AMG 329/HZN-1116 Phase 2 in Sjögren’s is still ongoing, which argues against any clear positive or negative public readout for NCT06312020 yet.

Found Apr 1, 2026, 7:53 PMReviewed Apr 1, 2026, 7:55 PM
Sponsoramgen.comFeb 3, 2026, 12:00 AM
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
Amgen lists AMG 329 as a Phase 2 Sjögren’s program and says the study is ongoing, with no trial-specific efficacy interpretation or top-line result disclosed.
ClinicalTrialsclinicaltrials.govMar 15, 2024, 12:00 AM
Study Details | NCT06312020 | A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
ClinicalTrials.gov shows NCT06312020 as the HZN-1116/AMG 329 Phase 2 Sjögren’s study record; the available record is a study listing/update page rather than a posted positive or negative results announcement.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.